{"url_path":"/sec/nuvb/8-k/2026-06-30/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1811063/0001193125-26-290823-index.html","accession_number":"0001193125-26-290823","cik":"0001811063","ticker":"NUVB","issuer_name":"Nuvation Bio Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1811063/0001193125-26-290823-index.html","primary_entity_key":"0001811063","primary_entity_name":"Nuvation Bio Inc."},"word_count":209,"has_tables":true,"body_markdown":"Item 1.02 Termination of a Material Definitive Agreement.\n\nThe information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.\n\nIn connection with the Offering and the issuance of Notes thereunder, on June 30, 2026, the Company completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $58.5 million in the aggregate (the “Payoff Amount”), under the Loan Agreement. Upon receipt by the Agent of the Payoff Amount on June 30, 2026, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.\n\nA summary of the material terms of the Loan Agreement is contained in the Form 8-K filed by the Company with the SEC on March 6, 2025 and is incorporated herein by reference. The description of the Loan Agreement therein is qualified in its entirety by reference to the full text of the Loan Agreement, which was filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 7, 2025."}